Analyst Price Targets — PSNL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 17, 2026 10:50 am | — | Needham | $17.00 | $15.58 | StreetInsider | Personalis (PSNL) PT Raised to $17 at NeedhamMember Login |
| May 12, 2026 12:32 pm | — | Morgan Stanley | $9.00 | $5.93 | TheFly | Personalis price target lowered to $9 from $10 at Morgan Stanley |
| May 11, 2026 11:15 am | Mark Massaro | BTIG | $11.00 | $5.98 | TheFly | Personalis price target lowered to $11 from $13 at BTIG |
| January 26, 2026 2:35 pm | Subbu Nambi | Guggenheim | $13.00 | $10.53 | TheFly | Personalis price target raised to $13 from $12 at Guggenheim |
| December 1, 2025 9:33 pm | Kallum Titchmarsh | Morgan Stanley | $11.00 | $9.68 | TheFly | Personalis assumed with an Equal Weight at Morgan Stanley |
| November 5, 2025 1:50 pm | Thomas Flaten | Lake Street | $11.00 | $8.25 | TheFly | Personalis price target raised to $11 from $9 at Lake Street |
| November 5, 2025 11:16 am | Mike Matson | Needham | $10.00 | $8.73 | StreetInsider | Personalis (PSNL) PT Raised to $10 at Needham |
| August 6, 2025 5:45 pm | Mark Massaro | BTIG | $6.00 | $4.41 | TheFly | Personalis price target lowered to $6 from $8 at BTIG |
| August 19, 2024 9:12 am | Thomas Flaten | Lake Street | $8.00 | $5.91 | TheFly | Personalis price target raised to $8 from $4 at Lake Street |
| August 19, 2024 6:08 am | Swayampakula Ramakanth | H.C. Wainwright | $9.00 | $5.99 | TheFly | Personalis price target raised to $9 from $7.50 at H.C. Wainwright |
Latest News for PSNL
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) marking for its NeXT Personal Dx test. This critical regulatory milestone enables the clinical use of Personalis' ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing…
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union's In Vitro Diagnostic Regulation (IVDR). The CE Mark represents an important regulatory milestone, ensuring that…
This cancer genomics specialist, serving major biopharma and research clients, reported a notable insider sale in its latest SEC filing.
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. “Our ASCO data continues to build on a compelling body of evidence, including…
Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PSNL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.